ES2092170T3 - Antagonistas de receptores de fibrinogeno marcados con tritio, su utilizacion y procedimiento para su preparacion. - Google Patents

Antagonistas de receptores de fibrinogeno marcados con tritio, su utilizacion y procedimiento para su preparacion.

Info

Publication number
ES2092170T3
ES2092170T3 ES93106725T ES93106725T ES2092170T3 ES 2092170 T3 ES2092170 T3 ES 2092170T3 ES 93106725 T ES93106725 T ES 93106725T ES 93106725 T ES93106725 T ES 93106725T ES 2092170 T3 ES2092170 T3 ES 2092170T3
Authority
ES
Spain
Prior art keywords
marked
procedure
tritio
preparation
fibrinogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93106725T
Other languages
English (en)
Inventor
Johannes Weisenberger
Hans-Dieter Schubert
Karl-Heinz Switek
Guenter Linz
Frank Himmelsbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Dr Karl Thomae GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4214245A external-priority patent/DE4214245A1/de
Application filed by Dr Karl Thomae GmbH filed Critical Dr Karl Thomae GmbH
Application granted granted Critical
Publication of ES2092170T3 publication Critical patent/ES2092170T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/53—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS ANTAGONISTAS RECEPTORES DE FIBRINOGENO MARCADOS CON UN ATOMO DETECTABLE, QUE POSEE UNA AFINIDAD COMPARABLE O MAS ELEVADA FRENTE AL RECEPTOR COMO 125 J INOGENO MARCADOS CON TRITIO SEGUN LA REIVINDICACION 3 QUE EN PRESENCIA DE PROTEINAS EXTRAÑAS POR EJEMPLO DE ALBUMINA Y FIBRONOGENO PRESENTAN UNA AFINIDAD (KP) MENOR DE 500 NM FRENTE AL RECEPTOR, SU APLICACION COMO LIGANDOS PARA LAS PRUEBAS DE UNION RECEPTOR/FIBRINOGENO O PARA DETERMINAR LA CONCENTRACION DE ANTAGONISTAS RECEPTORES DE FIBRINOGENO Y PROCEDIMIENTO PARA SU OBTENCION.
ES93106725T 1992-04-28 1993-04-26 Antagonistas de receptores de fibrinogeno marcados con tritio, su utilizacion y procedimiento para su preparacion. Expired - Lifetime ES2092170T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4213930 1992-04-28
DE4214245A DE4214245A1 (de) 1992-04-30 1992-04-30 Tritiummarkierte fibrinogen-rezeptor-antagonisten, deren verwendung und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
ES2092170T3 true ES2092170T3 (es) 1996-11-16

Family

ID=25914315

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93106725T Expired - Lifetime ES2092170T3 (es) 1992-04-28 1993-04-26 Antagonistas de receptores de fibrinogeno marcados con tritio, su utilizacion y procedimiento para su preparacion.

Country Status (16)

Country Link
US (1) US5677466A (es)
EP (1) EP0567967B1 (es)
JP (1) JPH0650977A (es)
KR (1) KR940005271A (es)
AT (1) ATE140225T1 (es)
AU (1) AU670778B2 (es)
CA (1) CA2094963A1 (es)
DE (1) DE59303178D1 (es)
DK (1) DK0567967T3 (es)
ES (1) ES2092170T3 (es)
FI (1) FI931881A7 (es)
GR (1) GR3020740T3 (es)
IL (1) IL105519A0 (es)
MX (1) MX9302446A (es)
NO (1) NO180046C (es)
NZ (1) NZ247511A (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4304650A1 (de) * 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4324580A1 (de) * 1993-07-22 1995-01-26 Thomae Gmbh Dr K Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5925635A (en) * 1996-04-17 1999-07-20 Dupont Pharmaceuticals Company N-(amidinophenyl) cyclourea analogs as factor XA inhibitors
ATE268751T1 (de) 1997-11-20 2004-06-15 Teijin Ltd Biphenylamidin-derivate
NZ504324A (en) * 1997-11-20 2002-02-01 Teijin Ltd Biphenylamidine derivatives and pharmaceutical compositions thereof; which can be useful as anticoagulant inhibitors, and thrombus or embolus preventing agents
CA2360686A1 (en) 1999-01-28 2000-08-03 Teijin Limited Release-regulating preparations
US6822101B2 (en) 2002-09-16 2004-11-23 Abbott Laboratories Process for preparing amine-substituted benzofurans
WO2004024707A2 (en) * 2002-09-16 2004-03-25 Abbott Laboratories Process for preparing amine type substituted benzofurans
EP3489692A1 (de) * 2017-11-28 2019-05-29 Siemens Healthcare Diagnostics Products GmbH Prothrombinzeit-reagenz enthaltend einen eisenchelator

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039805A (en) * 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
DE4134467A1 (de) * 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4035961A1 (de) * 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4107857A1 (de) * 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4124942A1 (de) * 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4127404A1 (de) * 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Also Published As

Publication number Publication date
FI931881L (fi) 1993-10-29
DE59303178D1 (de) 1996-08-14
MX9302446A (es) 1994-03-31
NZ247511A (en) 1995-02-24
NO931528L (no) 1993-10-29
KR940005271A (ko) 1994-03-21
NO180046B (no) 1996-10-28
DK0567967T3 (da) 1996-11-18
FI931881A0 (fi) 1993-04-27
JPH0650977A (ja) 1994-02-25
ATE140225T1 (de) 1996-07-15
AU3715393A (en) 1993-11-04
IL105519A0 (en) 1993-08-18
GR3020740T3 (en) 1996-11-30
US5677466A (en) 1997-10-14
CA2094963A1 (en) 1993-10-29
FI931881A7 (fi) 1993-10-29
EP0567967B1 (de) 1996-07-10
EP0567967A1 (de) 1993-11-03
NO931528D0 (no) 1993-04-27
AU670778B2 (en) 1996-08-01
NO180046C (no) 1997-02-05

Similar Documents

Publication Publication Date Title
ES2103803T3 (es) Ensayo inmunocromatografico y metodo para utilizar el mismo.
ES2183801T3 (es) Composiciones del receptor de acetilcolina nicotinico neuronal humano y procedimientos que lo usan.
EA200200530A1 (ru) Гетероциклические замещенные пиразолоны
ES2130265T3 (es) Region de union al receptor de la toxina difterica.
EP0727215A3 (en) Central cholecystokinin antagonists for the treatment of psychiatric disorders
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
EA200100022A1 (ru) Композиции с контролируемым высвобождением пароксетина
NO960630L (no) Heterocykler anvendelige som neurokinin antagonister
EP1461061A4 (en) COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF DISEASES AND CONDITIONS RELATED TO CHEMOKINE RECEPTORS
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
PT1305286E (pt) Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento
YU7797A (sh) Kombinovana terapija za osteoporozu
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ES2096560T3 (es) Compuestos de benzocicloheptapiridina sustituida con fluor, composiciones y metodos para uso como compuestos antihistaminicos.
ES2098140T3 (es) Liosferas que contienen gonadotropina.
ES2092170T3 (es) Antagonistas de receptores de fibrinogeno marcados con tritio, su utilizacion y procedimiento para su preparacion.
BR9909486A (pt) Compostos calcilìticos
DE69231918D1 (de) Peptidantagonisten des bradykinin
ES2171969T3 (es) Combinacion fusible de estabilizadores.
ATE201880T1 (de) Oberflächenaktive zusammensetzungen und verfahren
BR0108454A (pt) Métodos para identificação e uso de antagonistas de receptor de adenosina a(2b) papa mediar a proliferação celular em mamìferos
EE05213B1 (et) Lmfotoksiin- β retseptori (LT- β-R) blokeeriva agensi kasutamine ja LT- β-R-i blokeerivat agensit ning CD40L-i blokeerivat agensit sisaldav farmatseutiline kompositsioon
CR6398A (es) Antagonistas de 5ht1 para terapia antidepresiva
ES2123949T3 (es) Procedimiento para la preparacion de intermediarios para la sintesis de agentes antifungicos.
EA200000198A1 (ru) 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 567967

Country of ref document: ES